Cancer Advances Inc. is a biotechnology company focused on impacting human health and the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio.
Cancer Advances is a wholly owned subsidiary of Cato BioVentures. The company's lead compound, Polyclonal Antibody Stimulator (PAS), is an immunomodulator used to treat gastrointestinal cancer. Please visit our Product page for more information on what is in development.
Hemodynamic Therapeutics Inc. (HTI) is developing its novel small molecule combination therapy (HTI-101) for obesity-related hypertension, one of the world's fastest growing cardiovascular disease markets.HTI-101 is in Phase 2 clinical development.
HTI was formed in 2004 as a majority-owned portfolio company of Cato BioVentures. Through its strategic development relationship with Cato BioVentures and its contract research and development affiliate, Cato Research Ltd., HTI is executing its phase 2 development program for HTI-101, a novel small molecule combination therapy for obesity-related hypertension (ORH), one of the world's fastest growing cardiovascular disease markets.
Contact us to learn about more companies
we have invested in and grown:
Call: 514-984-4431 or